<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32084385</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>Knocking out C9ORF72 Exacerbates Axonal Trafficking Defects Associated with Hexanucleotide Repeat Expansion and Reduces Levels of Heat Shock Proteins.</ArticleTitle><Pagination><StartPage>390</StartPage><EndPage>405</EndPage><MedlinePgn>390-405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2020.01.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(20)30031-X</ELocationID><Abstract><AbstractText>In amyotrophic lateral sclerosis (ALS) motor neurons (MNs) undergo dying-back, where the distal axon degenerates before the soma. The hexanucleotide repeat expansion (HRE) in C9ORF72 is the most common genetic cause of ALS, but the mechanism of pathogenesis is largely unknown with both gain- and loss-of-function mechanisms being proposed. To better understand C9ORF72-ALS pathogenesis, we generated isogenic induced pluripotent stem cells. MNs with HRE in C9ORF72 showed decreased axonal trafficking compared with gene corrected MNs. However, knocking out C9ORF72 did not recapitulate these changes in MNs from healthy controls, suggesting a gain-of-function mechanism. In contrast, knocking out C9ORF72 in MNs with HRE exacerbated axonal trafficking defects and increased apoptosis as well as decreased levels of HSP70 and HSP40, and inhibition of HSPs exacerbated ALS phenotypes in MNs with HRE. Therefore, we propose that the HRE in C9ORF72 induces ALS pathogenesis via a combination of gain- and loss-of-function mechanisms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abo-Rady</LastName><ForeName>Masin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Technische Universit&#xe4;t Dresden, Center for Regenerative Therapies TU Dresden (CRTD), 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalmbach</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Arun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schludi</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for System Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janosch</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Ulm, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freitag</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Klinische Genetik, Medizinische Fakult&#xe4;t Carl Gustav Carus, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bickle</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahlert</LastName><ForeName>Anne-Karin</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Klinische Genetik, Medizinische Fakult&#xe4;t Carl Gustav Carus, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanov</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Technische Universit&#xe4;t Dresden, Center for Regenerative Therapies TU Dresden (CRTD), 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Hannes</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany; Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology and Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staege</LastName><ForeName>Selma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Just</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Ulm, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatnagar</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Verge Genomics, San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for System Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Technische Universit&#xe4;t Dresden, Center for Regenerative Therapies TU Dresden (CRTD), 01307 Dresden, Germany; Department of Neurology, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany; Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology and Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany; German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, 18147 Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegner</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany. Electronic address: wegner.florian@mh-hannover.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sterneckert</LastName><ForeName>Jared L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Technische Universit&#xe4;t Dresden, Center for Regenerative Therapies TU Dresden (CRTD), 01307 Dresden, Germany. Electronic address: jared.sterneckert@tu-dresden.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410027">KNK 437</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="N">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073659" MajorTopicYN="N">Gain of Function Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="Y">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="N">Pyrrolidinones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">HSP40</Keyword><Keyword MajorTopicYN="N">HSP70</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">axonal trafficking</Keyword><Keyword MajorTopicYN="N">disease modeling</Keyword><Keyword MajorTopicYN="N">gene editing</Keyword><Keyword MajorTopicYN="N">heat shock proteins</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32084385</ArticleId><ArticleId IdType="pmc">PMC7066330</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2020.01.010</ArticleId><ArticleId IdType="pii">S2213-6711(20)30031-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Atassi N., David W., Cudkowicz M., Schoenfeld D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565&#x2013;e574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J., Gendron T.F., Prudencio M., Sasaguri H., Zhang Y.J., Castanedes-Casey M., Lee C.W., Jansen-West K., Kurti A., Murray M.E. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348:1151&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitiprolu M., Jagow C., Tremblay V., Bondy-Chorney E., Paris G., Savard A., Palidwor G., Barry F.A., Zinman L., Keith J. A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. Nat. Commun. 2018;9:2794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052026</ArticleId><ArticleId IdType="pubmed">30022074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S., Lattante S., Le Ber I., Latouche M., Tostivint H., Brice A., Kabashi E. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:180&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin A.C., Burr K., Borooah S., Foster J.D., Cleary E.M., Geti I., Vallier L., Shaw C.E., Chandran S., Miles G.B. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat. Commun. 2015;6:5999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P., Sellier C., Mackenzie I.R.A., Cheng C.-Y., Tahraoui-Bories J., Martinat C., Pasterkamp R.J., Prudlo J., Edbauer D., Oulad-Abdelghani M. Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol. Commun. 2018;6:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganassi M., Mateju D., Bigi I., Mediani L., Poser I., Lee H.O., Seguin S.J., Morelli F.F., Vinet J., Leo G. A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism. Mol. Cell. 2016;63:796&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">27570075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., Van Langenhove T., van der Zee J., Sleegers K., Philtjens S., Kleinberger G., Janssens J., Bettens K., Van Cauwenberghe C., Pereson S. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012;11:54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hruscha A., Krawitz P., Rechenberg A., Heinrich V., Hecht J., Haass C., Schmid B. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development. 2013;140:4982&#x2013;4987.</Citation><ArticleIdList><ArticleId IdType="pubmed">24257628</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-nejad P., Drenner K., Schulte D. Gain of toxicity from ALS/FTD-Linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.-H., Zhang P., Kim H.J., Mitrea D.M., Sarkar M., Freibaum B.D., Cika J., Coughlin M., Messing J., Molliex A. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167:774&#x2013;788.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.R., King O.D., Shorter J., Gitler A.D. Stress granules as crucibles of ALS pathogenesis. J.&#xa0;Cell Biol. 2013;201:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Loschi M., Leishman C.C., Berardone N., Boccaccio G.L. Dynein and kinesin regulate stress-granule and P-body dynamics. J.&#xa0;Cell Sci. 2009;122:3973&#x2013;3982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773196</ArticleId><ArticleId IdType="pubmed">19825938</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Renton A.E., Mok K., Dopper E.G.P., Waite A., Rollinson S., Chi&#xf2; A., Restagno G., Nicolaou N., Simon-Sanchez J. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordes D.A., Prudencio M., Goodman L.D., Klim J.R., Moccia R., Limone F., Pietilainen O., Chowdhary K., Dickson D.W., Rademakers R. Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. Acta Neuropathol. Commun. 2018;6:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6031111</ArticleId><ArticleId IdType="pubmed">29973287</ArticleId></ArticleIdList></Reference><Reference><Citation>Naujock M., Stanslowsky N., Bufler S., Naumann M., Reinhardt P., Sterneckert J., Kefalakes E., Kassebaum C., Bursch F., Lojewski X. 4-Aminopyridine induced activity rescues hypoexcitable motor neurons from amyotrophic lateral sclerosis patient-derived induced pluripotent stem cells. Stem Cells. 2016;34:1563&#x2013;1575.</Citation><ArticleIdList><ArticleId IdType="pubmed">26946488</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M., Pal A., Goswami A., Lojewski X., Japtok J., Vehlow A., Naujock M., G&#xfc;nther R., Jin M., Stanslowsky N. Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat. Commun. 2018;9:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5780468</ArticleId><ArticleId IdType="pubmed">29362359</ArticleId></ArticleIdList></Reference><Reference><Citation>Niblock M., Smith B.N., Lee Y.B., Sardone V., Topp S., Troakes C., Al-Sarraj S., Leblond C.S., Dion P.A., Rouleau G.A. Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. Acta Neuropathol. Commun. 2016;4:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766718</ArticleId><ArticleId IdType="pubmed">26916632</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A., Kenna K.P., Renton A.E., Ticozzi N., Faghri F., Chia R., Dominov J.A., Kenna B.J., Nalls M.A., Keagle P. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268&#x2013;1283.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal A., Glass H., Naumann M., Kreiter N., Japtok J., Sczech R., Hermann A. High content organelle trafficking enables disease state profiling as powerful tool for disease modelling. Sci. Data. 2018;5:180241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233479</ArticleId><ArticleId IdType="pubmed">30422121</ArticleId></ArticleIdList></Reference><Reference><Citation>Parone P.A., Da Cruz S., Han J.S., McAlonis-Downes M., Vetto A.P., Lee S.K., Tseng E., Cleveland D.W. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. J.&#xa0;Neurosci. 2013;33:4657&#x2013;4671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711648</ArticleId><ArticleId IdType="pubmed">23486940</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Belzil V.V., Batra R., Ross C.A., Gendron T.F., Pregent L.J., Murray M.E., Overstreet K.K., Piazza-Johnston A.E., Desaro P. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat. Neurosci. 2015;18:1175&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I., Jonnakuty C., LaMonte B.H., Holzbaur E.L.F., Tokito M., Mann E., Floeter M.K., Bidus K., Drayna D., Oh S.J. Mutant dynactin in motor neuron disease. Nat. Genet. 2003;33:455&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D., O'Rourke J.G., Meera P., Muhammad A.K.M.G., Grant S., Simpkinson M., Bell S., Carmona S., Ornelas L., Sahabian A. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Translational Med. 2013;5:208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj B.T., Livesey M.R., Zhao C., Gregory J.M., James O.T., Cleary E.M., Chouhan A.K., Gane A.B., Perkins E.M., Dando O. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca(2+)-permeable AMPA receptor-mediated excitotoxicity. Nat. Commun. 2018;9:347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Lin S., Staats K.A., Li Y., Chang W.-H., Hung S.-T., Hendricks E., Linares G.R., Wang Y., Son E.Y. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 2018;24:313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Sanchez J., Dopper E.G., Cohn-Hokke P.E., Hukema R.K., Nicolaou N., Seelaar H., de Graaf J.R., de Koning I., van Schoor N.M., Deeg D.J. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012;135:723&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">22300876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabet R., Schaeffer L., Freyermuth F., Jambeau M., Workman M., Lee C.-Z., Lin C.-C., Jiang J., Jansen-West K., Abou-Hamdan H. CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Nat. Commun. 2018;9:152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5764992</ArticleId><ArticleId IdType="pubmed">29323119</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M., Mullen B., Heckman M.G., Baker M.C., DeJesus-Hernandez M., Brown P.H., Murray M.E., Hsiung G.Y., Stewart H., Karydas A.M. Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol. Aging. 2014;35:2421.e13&#x2013;2421.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105839</ArticleId><ArticleId IdType="pubmed">24866401</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Kiskinis E., Mellin C., Wiskow O., Han S.S., Sandoe J., Perez N.P., Williams L.A., Lee S., Boulting G. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite A.J., Baumer D., East S., Neal J., Morris H.R., Ansorge O., Blake D.J. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging. 2014;35:1779.e5&#x2013;1779.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota S., Kitahara M., Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000;60:2942&#x2013;2948.</Citation><ArticleIdList><ArticleId IdType="pubmed">10850441</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Almeida S., Lu Y., Nishimura A.L., Peng L., Sun D., Wu B., Karydas A.M., Tartaglia M.C., Fong J.C. Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. PLoS One. 2013;8:e76055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3797144</ArticleId><ArticleId IdType="pubmed">24143176</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>